Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Yu-Tzu Tai, Ph.D.

Co-Author

This page shows the publications co-authored by Yu-Tzu Tai and Teru Hideshima.
Connection Strength

3.494
  1. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13162-13167.
    View in: PubMed
    Score: 0.176
  2. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49.
    View in: PubMed
    Score: 0.111
  3. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30; 113(18):4309-18.
    View in: PubMed
    Score: 0.103
  4. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37.
    View in: PubMed
    Score: 0.093
  5. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91.
    View in: PubMed
    Score: 0.093
  6. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
    View in: PubMed
    Score: 0.091
  7. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82.
    View in: PubMed
    Score: 0.086
  8. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
    View in: PubMed
    Score: 0.083
  9. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906.
    View in: PubMed
    Score: 0.080
  10. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
    View in: PubMed
    Score: 0.077
  11. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
    View in: PubMed
    Score: 0.074
  12. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8.
    View in: PubMed
    Score: 0.071
  13. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9.
    View in: PubMed
    Score: 0.067
  14. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2021 Jul 21.
    View in: PubMed
    Score: 0.061
  15. ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun; 7(23).
    View in: PubMed
    Score: 0.060
  16. Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discov. 2021 07; 2(4):370-387.
    View in: PubMed
    Score: 0.060
  17. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000 Dec 01; 165(11):6347-55.
    View in: PubMed
    Score: 0.058
  18. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020 11 12; 136(20):2334-2345.
    View in: PubMed
    Score: 0.058
  19. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000 Nov 01; 96(9):2943-50.
    View in: PubMed
    Score: 0.058
  20. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res. 2000 Mar; 6(3):1180-9.
    View in: PubMed
    Score: 0.055
  21. Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods. 2000 Feb 21; 235(1-2):11-9.
    View in: PubMed
    Score: 0.055
  22. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia. 2020 01; 34(1):196-209.
    View in: PubMed
    Score: 0.052
  23. Correction: Dual Inhibition of Canonical and Noncanonical NF-?B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clin Cancer Res. 2019 May 01; 25(9):2938.
    View in: PubMed
    Score: 0.052
  24. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2019 01; 33(1):171-180.
    View in: PubMed
    Score: 0.049
  25. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947.
    View in: PubMed
    Score: 0.048
  26. MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926.
    View in: PubMed
    Score: 0.046
  27. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237.
    View in: PubMed
    Score: 0.045
  28. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109.
    View in: PubMed
    Score: 0.043
  29. MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97.
    View in: PubMed
    Score: 0.042
  30. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
    View in: PubMed
    Score: 0.041
  31. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50.
    View in: PubMed
    Score: 0.041
  32. Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847.
    View in: PubMed
    Score: 0.041
  33. Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015 Sep; 5(9):972-87.
    View in: PubMed
    Score: 0.040
  34. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
    View in: PubMed
    Score: 0.040
  35. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
    View in: PubMed
    Score: 0.040
  36. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 Aug 15; 74(16):4458-69.
    View in: PubMed
    Score: 0.037
  37. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13.
    View in: PubMed
    Score: 0.037
  38. Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55.
    View in: PubMed
    Score: 0.035
  39. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
    View in: PubMed
    Score: 0.033
  40. Dual inhibition of canonical and noncanonical NF-?B pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012 Sep 01; 18(17):4669-81.
    View in: PubMed
    Score: 0.033
  41. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31.
    View in: PubMed
    Score: 0.032
  42. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011 Oct 15; 17(20):6500-9.
    View in: PubMed
    Score: 0.031
  43. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
    View in: PubMed
    Score: 0.028
  44. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
    View in: PubMed
    Score: 0.028
  45. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 01; 15(23):7144-52.
    View in: PubMed
    Score: 0.027
  46. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
    View in: PubMed
    Score: 0.027
  47. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood. 2009 Sep 24; 114(13):2699-708.
    View in: PubMed
    Score: 0.027
  48. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
    View in: PubMed
    Score: 0.026
  49. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009 Jun 15; 69(12):5082-90.
    View in: PubMed
    Score: 0.026
  50. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9.
    View in: PubMed
    Score: 0.026
  51. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar; 14(1):99-127.
    View in: PubMed
    Score: 0.026
  52. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther. 2009 Jan; 8(1):26-35.
    View in: PubMed
    Score: 0.026
  53. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
    View in: PubMed
    Score: 0.024
  54. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
    View in: PubMed
    Score: 0.024
  55. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9.
    View in: PubMed
    Score: 0.023
  56. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene. 2008 Jan 31; 27(6):721-31.
    View in: PubMed
    Score: 0.023
  57. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul; 35(7):1038-46.
    View in: PubMed
    Score: 0.023
  58. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res. 2007 Feb 15; 67(4):1680-8.
    View in: PubMed
    Score: 0.022
  59. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19478-83.
    View in: PubMed
    Score: 0.022
  60. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15; 109(4):1669-77.
    View in: PubMed
    Score: 0.022
  61. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56.
    View in: PubMed
    Score: 0.021
  62. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006 Nov 15; 108(10):3441-9.
    View in: PubMed
    Score: 0.021
  63. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 01; 24(38):5888-96.
    View in: PubMed
    Score: 0.020
  64. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84.
    View in: PubMed
    Score: 0.020
  65. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12.
    View in: PubMed
    Score: 0.020
  66. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53.
    View in: PubMed
    Score: 0.019
  67. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6.
    View in: PubMed
    Score: 0.019
  68. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
    View in: PubMed
    Score: 0.018
  69. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem. 2004 May 14; 279(20):21658-65.
    View in: PubMed
    Score: 0.018
  70. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66.
    View in: PubMed
    Score: 0.018
  71. Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol. 2003 Dec; 123(5):869-78.
    View in: PubMed
    Score: 0.018
  72. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004 May 01; 103(9):3474-9.
    View in: PubMed
    Score: 0.018
  73. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 Oct 01; 63(19):6187-94.
    View in: PubMed
    Score: 0.018
  74. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86.
    View in: PubMed
    Score: 0.017
  75. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
    View in: PubMed
    Score: 0.017
  76. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6.
    View in: PubMed
    Score: 0.017
  77. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.
    View in: PubMed
    Score: 0.017
  78. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801.
    View in: PubMed
    Score: 0.017
  79. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
    View in: PubMed
    Score: 0.017
  80. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
    View in: PubMed
    Score: 0.016
  81. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82.
    View in: PubMed
    Score: 0.016
  82. beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20.
    View in: PubMed
    Score: 0.016
  83. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001 Dec; 15(12):1950-61.
    View in: PubMed
    Score: 0.016
  84. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001 Jul 15; 98(2):428-35.
    View in: PubMed
    Score: 0.015
  85. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 01; 98(1):210-6.
    View in: PubMed
    Score: 0.015
  86. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 2000 Nov 01; 96(9):3147-53.
    View in: PubMed
    Score: 0.014
  87. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000 Sep 08; 275(36):27845-50.
    View in: PubMed
    Score: 0.014
  88. Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid. 2000 Jun; 7(2):126-32.
    View in: PubMed
    Score: 0.014
  89. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood. 2000 Feb 01; 95(3):1039-46.
    View in: PubMed
    Score: 0.014
  90. Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. Cancer Res. 1999 Mar 15; 59(6):1192-5.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.